Cost‐effectiveness and cost‐utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trial
TDM-based mercaptopurine treatment in UC patients failing 5-aminosalicylates is a cost-effective strategy from a societal perspective.
Authors
- Nanne K.H. de Boer (ORCID: https://orcid.org/0000-0001-8357-9887)
- Dirk van Asseldonk
- Adriaan A. van Bodegraven (ORCID: https://orcid.org/0000-0003-2636-303X)
- Sara van Gennep (ORCID: https://orcid.org/0000-0002-9843-0134)
- Mark Löwenberg (ORCID: https://orcid.org/0000-0002-4975-9945)
- Marit van Barreveld (ORCID: https://orcid.org/0000-0002-4672-2477)
- Melanie S. Hulshoff (ORCID: https://orcid.org/0000-0002-1792-2533)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Marjolijn Duijvestein (ORCID: https://orcid.org/0000-0003-4814-9376)
- Adriaan Volkers (ORCID: https://orcid.org/0000-0002-9547-1627)
- Rachel West (ORCID: https://orcid.org/0000-0003-1914-9393)
- Marcel G.W. Dijkgraaf
- Jeroen M. Jansen
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Sint Franciscus Gasthuis (NL)
- Noordwest Ziekenhuisgroep (NL)
- OLVG (NL)
- Zuyderland Medisch Centrum (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- United European Gastroenterology Journal
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1002/ueg2.12661
- Citations
- 1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Teva Pharmaceutical Industries
- Celgene
- Celltrion
- ZonMw
- Tillotts Pharma
- Eurostars